NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-17-205 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Funding Opportunity PAR-17-201 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Notice NOT-HL-17-492 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-211 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this program announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.
Funding Opportunity PA-17-212 from the NIH Guide for Grants and Contracts. 93.273 Funding Opportunity Purpose This Funding Opportunity Announcement (FOA) encourages applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this FOA is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.
Funding Opportunity PA-17-213 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this FOA is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.
Notice NOT-PM-17-003 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-18-003 from the NIH Guide for Grants and Contracts. The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.
Funding Opportunity PAR-17-206 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue support for the program referred to as the Alliance of Glycobiologists for Cancer Research (http://glycomics.cancer.gov). Through this FOA, the NCI encourages research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycan-based abnormalities to serve as biomarkers for early cancer detection or risk assessment. These changes may be studied at the level of glycoproteins, glycolipids, glycosaminoglycans, and/or their binding proteins. In their applications, applicants are encouraged to address the ability of these biomarker candidates to accurately distinguish individuals with cancer from those without. It is expected that the most promising biomarker candidates will ultimately be tested in clinical validation studies, although such validation studies are not required for the proposed projects. All investigators with appropriate expertise and capabilities, irrespective of any prior association with this Alliance, are encouraged to consider applying to this FOA.
Funding Opportunity PAR-17-207 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is intended to support research applications that are focused on mechanisms that mediate alterations in glycosylation during oncogenesis. The goal of this FOA is to advance our knowledge of altered glycosylation or other modifications in carbohydrate structure in cancer to determine whether it is the cause or the result of neoplastic transformation. Because the research is intended to examine the biology of how modifications in carbohydrate structure influence malignancy during different stages of the disease, this FOA will support research teams that have complementary expertise in glycobiology and cancer biology to focus on mechanisms that mediate alterations in glycosylation during oncogenesis.
Funding Opportunity PAR-17-209 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of General Medical Sciences (NIGMS) R25 program is to support educational activities that enhance the diversity of the biomedical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences.
Funding Opportunity PAR-17-210 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of General Medical Sciences (NIGMS) R25 program is to support educational activities that enhance the diversity of the biomedical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Curriculum or Methods Development. A program application must include each activity, and describe how they will be synergized to make a comprehensive program.
Funding Opportunity PAR-17-208 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to transition the core resources and biomedical research activities of Centers of Biomedical Research Excellence (COBRE) into independence and sustainability.
Notice NOT-NS-17-018 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-17-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and with possible collaboration with Cohen Veterans Bioscience, encourages Research Project Grant (R01) applications that will further the development, validation and/or application of animal models for mechanistic studies on the comorbidity of PTSD and alcohol use disorders.
Funding Opportunity RFA-NS-17-012 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications that address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States, including in health disparities populations, when a patient, relative, or care provider indicates concern. Proposed clinical paradigms should utilize tools that are simple to use, standardized, and ideally take five minutes or less to administer in a primary care clinical setting.
Funding Opportunity RFA-DA-18-001 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.
Funding Opportunity PAR-17-204 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.
Funding Opportunity PAR-17-203 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.
Notice NOT-AI-17-016 from the NIH Guide for Grants and Contracts